On 12 Nov 2026 our base value for Gilead Sciences is $85.46 a share, 49.1% below its $167.95 close; 0 of 1 valuation methods put it above the price.
| Method | Value | vs price | Basis |
|---|---|---|---|
| Discounted cash flow | — | — | perpetuity refused: the 7.65% discount rate sits 1.11pt from the 6.54% the model would compound (floor 2pt) — growth and discounting cancel through the explicit window, so the answer is the terminal block and the house fade, not this company's cash flows. The target rests on the exit multiple alone |
| Exit multiple (P/E) | — | — | the model values the equity at -$9.90 — a negative figure is not a low price, it is a projection of losses, and no share price follows from it |
| Sum of the parts | — | — | no sum of the parts: this run holds no segment disclosure for the name |
| Price to sales | $85.46 | -49.1% | the stock's own median price-to-sales of 3.45× |
| Tangible book | — | — | used only for lenders, where book value is the business |
| Price to FFO (REITs) | — | — | used only for REITs |
Each working is rebuilt by code from the valuation's own figures and checked against the published value.
The base value is the average of the methods kept in it:
| Method | Value |
|---|---|
| Price to sales | $85.46 |
One method is kept, so the base value is its value: $85.46
Base value $85.46 a share
One-year price simulation: a 10% chance the price is below $121.86 and a 10% chance it is above $248.69 in a year; a 55% chance it is higher than today's $167.95, from 27.69% volatility. The simulation assumes the price drifts up at our discount rate of 7.65% a year.
| Week | Price | Base value |
|---|---|---|
| 2 Oct 2026 | $144.74 | $210.63 |
| 9 Oct 2026 | $151.17 | $215.39 |
| 16 Oct 2026 | $156.19 | $84.53 |
| 23 Oct 2026 | $156.04 | $84.53 |
| 30 Oct 2026 | $170.68 | $85.46 |
| 6 Nov 2026 | $166.89 | $85.46 |
| 12 Nov 2026 | $167.95 | $85.46 |
Data as of 12 Nov 2026; financials to 30 Sep 2026. Sources: company filings via EODHD, SEC EDGAR, US Treasury. How these values are computed. Not investment advice.
Run a full Desk Run on GILD · Gilead Sciences company page · Call and put prices